Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2021

Nov 15, 2021

SELL
$3.1 - $4.32 $631,287 - $879,729
-203,641 Closed
0 $0
Q2 2021

Aug 16, 2021

SELL
$4.45 - $9.91 $2.97 Million - $6.61 Million
-666,587 Reduced 76.6%
203,641 $906,000
Q1 2021

May 18, 2021

BUY
$7.76 - $10.43 $491,425 - $660,511
63,328 Added 7.85%
870,228 $7.96 Million
Q4 2020

Feb 16, 2021

BUY
$4.13 - $10.14 $317,597 - $779,766
76,900 Added 10.53%
806,900 $8.18 Million
Q3 2020

Nov 03, 2020

BUY
$3.91 - $7.15 $2.07 Million - $3.78 Million
528,752 Added 262.74%
730,000 $3.1 Million
Q2 2020

Aug 14, 2020

BUY
$2.6 - $7.32 $523,244 - $1.47 Million
201,248 New
201,248 $1.4 Million

Others Institutions Holding DMAC

About DiaMedica Therapeutics Inc.


  • Ticker DMAC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 26,443,100
  • Market Cap $126M
  • Description
  • DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type...
More about DMAC
Track This Portfolio

Track Corriente Advisors, LLC Portfolio

Follow Corriente Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Corriente Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Corriente Advisors, LLC with notifications on news.